Glenmark Pharmaceuticals , a leading global pharmaceutical company, has announced significant developments in its operations, showcasing strong performance and plans for new product launches.

FY26 Guidance and Financial Performance

Glenmark Pharmaceuticals remains confident of achieving its FY26 guidance of 10-12% revenue growth and 19-20% Ebitda margin. Executive Director and CFO Anurag Mantri stated that margins will stabilize at 23% from Q3 onwards. The company's consolidated revenue rose 0.60% to Rs 3,264.40 crore in Q1, while adjusted profit after tax declined to Rs 312.90 crore from Rs 340.20 crore in the previous year.

Global Business Performance

The European business has shown impressive growth, with over 25% CAGR for three years and double-digit momentum expected from Q2, supported by two new launches. The US business recorded 9% quarter-on-quarter growth in Q1, driven by injectable product launches, with three additional injectable launches planned for Q2.

However, the India business faced pressure in Q1 due to underperformance in its diabetes portfolio, though supply chain issues have been resolved. The company is targeting 20% CAGR growth in India.

Mycamine's Strong Performance

Glenmark reported that Mycamine for Injection, an antifungal medication, has achieved impressive annual sales of approximately $60.70 million. This figure underscores the drug's importance in Glenmark's portfolio and its strong market presence in the antifungal segment.

Upcoming Launch: Micafungin Injection

In a strategic move to expand its product offerings, Glenmark Pharma's US division is gearing up to introduce Micafungin Injection to the market. The company plans to launch this medication in two formulations:

• 50 mg
• 100 mg

Micafungin, like Mycamine, belongs to the echinocandin class of antifungal drugs. These medications are crucial in treating various fungal infections, particularly in hospitalized patients.

Strategic Implications

The introduction of Micafungin Injection represents Glenmark's commitment to broadening its presence in the antifungal market. By offering multiple formulations, the company aims to cater to diverse patient needs and potentially capture a larger market share.

The success of Mycamine and the forthcoming launch of Micafungin Injection highlight Glenmark Pharmaceuticals' strong position in the specialty pharmaceutical market. These developments are expected to contribute to the company's growth trajectory in the US market, which is a key region for many global pharmaceutical firms.

As Glenmark continues to strengthen its product pipeline and market presence, investors and industry observers will be keen to see how these moves impact the company's overall performance in the coming quarters.

Glenmark Pharmaceuticals Ltd. , a global pharmaceutical company, has announced its financial results for the first quarter of fiscal year 2026 (Q1 FY26) while also providing an optimistic outlook for its European and emerging markets business.

Growth Forecast for Europe and Emerging Markets

Glenmark Pharma anticipates strong double-digit growth in its Europe and emerging markets region starting from the second quarter of FY26. This positive outlook comes as the company aims to capitalize on its expanding presence in these geographical segments.

Q1 FY26 Financial Highlights

For the quarter ended June 30, 2025, Glenmark reported the following key financial metrics:

• Consolidated revenue: Rs. 32,644.00 Mn, a slight increase of 0.60% year-over-year (YoY)
• EBITDA: Rs. 5,805.00 Mn, with an EBITDA margin of 17.80%
• Adjusted Profit After Tax: Rs. 3,129.00 Mn, with an adjusted PAT margin of 9.60%

Performance Across Key Markets

Management Commentary

Glenn Saldanha, Chairman & Managing Director of Glenmark Pharmaceuticals Ltd., commented on the results: "In Q1FY26, our U.S. business delivered QoQ growth, driven by a combination of injectable and partnered products launches. Our Europe and Emerging markets businesses have recorded >25% CAGR and >10% CAGR respectively over the last three years, and we expect the region to deliver a double-digit growth from the second quarter onwards."

Strategic Developments

• The company's recent IGI-AbbVie global licensing agreement for ISB 2001 has been highlighted as a strong validation of Glenmark's innovation capabilities.
• Glenmark's strategy focuses on driving growth across markets while advancing branded, specialty, and innovative products.

Exceptional Item

The company reported an exceptional item related to a settlement in an antitrust lawsuit in the United States. Glenmark has agreed to settle with the putative direct purchaser class for a total of US$ 37.75 million, subject to court approval. This settlement amount has been provisioned in the Q1 FY26 results.

Outlook

Glenmark remains confident in its strategy to drive growth across its markets, with a particular focus on the promising outlook for its European and emerging markets businesses. The company continues to advance its branded, specialty, and innovative products portfolio to deliver long-term value for stakeholders.

As Glenmark Pharmaceuticals navigates the evolving pharmaceutical landscape, its diversified geographical presence and focus on innovation are expected to play crucial roles in its future growth trajectory.